{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:26:19Z","timestamp":1793996779270,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03201-9","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:23:31Z","timestamp":1757607811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts"],"prefix":"10.1208","volume":"26","author":[{"given":"Mounika","family":"Aare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Chary","family":"Padakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9192-8143","authenticated-orcid":false,"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"607","key":"3201_CR1","doi-asserted-by":"publisher","first-page":"120943","DOI":"10.1016\/j.ijpharm.2021.120943","volume":"25","author":"N Patel","year":"2021","unstructured":"Patel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, et al. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. Int J Pharm. 2021;25(607):120943.","journal-title":"Int J Pharm"},{"key":"3201_CR2","doi-asserted-by":"crossref","unstructured":"Shen K, Li X, Zhao S, Zhang X, Yu L, Li J, et al. Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance. Discov Oncol. 2025;16(1):1144.","DOI":"10.1007\/s12672-025-02989-z"},{"issue":"13","key":"3201_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137079","volume":"23","author":"F Canino","year":"2022","unstructured":"Canino F, Piacentini F, Omarini C, Toss A, Barbolini M, Vici P, et al. Role of intrinsic subtype analysis with PAM50 in hormone receptors positive HER2 negative metastatic breast cancer: a systematic review. Int J Mol Sci. 2022;23(13): 7079.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3201_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11033-021-06863-3","volume":"49","author":"F Miranda","year":"2022","unstructured":"Miranda F, Prazeres H, Mendes F, Martins D, Schmitt F. Resistance to endocrine therapy in HR + and\/or HER2 + breast cancer: the most promising predictive biomarkers. Mol Biol Rep. 2022;49(1):717\u201333.","journal-title":"Mol Biol Rep"},{"key":"3201_CR5","doi-asserted-by":"publisher","unstructured":"Tiwari H, Singh S, Sharma S, Gupta P, Verma A, Chattopadhaya A, et al. Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities. Med Res Rev. 2025(3). https:\/\/doi.org\/10.1002\/med.22090.","DOI":"10.1002\/med.22090"},{"issue":"2","key":"3201_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.25122\/jml-2021-0108","volume":"15","author":"A Baranova","year":"2022","unstructured":"Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life. 2022;15(2):153\u201361.","journal-title":"J Med Life"},{"issue":"4","key":"3201_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"M Nikolaou","year":"2018","unstructured":"Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309\u201318.","journal-title":"Clin Exp Metastasis"},{"key":"3201_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00193","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020. https:\/\/doi.org\/10.3389\/fmolb.2020.00193.","journal-title":"Front Mol Biosci"},{"issue":"98","key":"3201_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","volume":"1","author":"Q Hu","year":"2016","unstructured":"Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev. 2016;1(98):19\u201334.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3201_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/ph16020155","volume":"16","author":"M Luz-Veiga","year":"2023","unstructured":"Luz-Veiga M, Azevedo-Silva J, Fernandes JC. Beyond pain relief: a review on cannabidiol potential in medical therapies. Pharmaceuticals. 2023;16(2):155.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"3201_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ph13090219","volume":"13","author":"SA Millar","year":"2020","unstructured":"Millar SA, Maguire RF, Yates AS, O\u2019Sullivan SE. Towards better delivery of cannabidiol (CBD). Pharmaceuticals. 2020;13(9):219.","journal-title":"Pharmaceuticals"},{"issue":"18","key":"3201_CR12","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.3390\/molecules27186070","volume":"27","author":"L Grifoni","year":"2022","unstructured":"Grifoni L, Vanti G, Donato R, Sacco C, Bilia AR. Promising nanocarriers to enhance solubility and bioavailability of cannabidiol for a plethora of therapeutic opportunities. Molecules. 2022;27(18):6070.","journal-title":"Molecules"},{"issue":"663","key":"3201_CR13","doi-asserted-by":"publisher","first-page":"124375","DOI":"10.1016\/j.ijpharm.2024.124375","volume":"30","author":"M Aare","year":"2024","unstructured":"Aare M, Bagde A, Nathani A, Rishi AK, Singh M. Enhanced oral bioavailability and in vitro evaluation of cannabidiol camel milk-derived exosome formulation in resistant MDA-MB-231 and MDA-MB-468 breast cancer cells. Int J Pharm. 2024;30(663):124375.","journal-title":"Int J Pharm"},{"key":"3201_CR14","doi-asserted-by":"publisher","unstructured":"Jivani A, Shinde RK. A comprehensive review of taxane treatment in breast cancer: clinical perspectives and toxicity profiles. Cureus. 2024;16(4). https:\/\/doi.org\/10.7759\/cureus.59266.","DOI":"10.7759\/cureus.59266"},{"issue":"28","key":"3201_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14(28): 1405491.","journal-title":"Front Oncol"},{"issue":"84","key":"3201_CR16","doi-asserted-by":"publisher","first-page":"104494","DOI":"10.1016\/j.jddst.2023.104494","volume":"1","author":"G Mustafa","year":"2023","unstructured":"Mustafa G, Hassan D, Ruiz-Pulido G, Pourmadadi M, Eshaghi MM, Behzadmehr R, et al. Nanoscale drug delivery systems for cancer therapy using paclitaxel\u2014 A review of challenges and latest progressions. J Drug Deliv Sci Technol. 2023;1(84):104494.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"3201_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/10781552231208978","volume":"30","author":"S Wile\u0144ski","year":"2024","unstructured":"Wile\u0144ski S, Koper A, \u015aledzi\u0144ska P, Bebyn M, Koper K. Innovative strategies for effective paclitaxel delivery: recent developments and prospects. J Oncol Pharm Pract. 2024;30(2):367\u201384.","journal-title":"J Oncol Pharm Pract"},{"issue":"188","key":"3201_CR18","doi-asserted-by":"publisher","first-page":"114445","DOI":"10.1016\/j.addr.2022.114445","volume":"1","author":"Q Gao","year":"2022","unstructured":"Gao Q, Feng J, Liu W, Wen C, Wu Y, Liao Q, et al. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Deliv Rev. 2022;1(188):114445.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3201_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.nano.2016.07.017","volume":"13","author":"R Yang","year":"2017","unstructured":"Yang R, Mondal G, Wen D, Mahato RI. Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomed Nanotechnol Biol Med. 2017;13(2):391\u2013401.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"26","key":"3201_CR20","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376.","journal-title":"N Engl J Med"},{"issue":"11","key":"3201_CR21","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1007\/s13346-022-01137-2","volume":"12","author":"SK Surapaneni","year":"2022","unstructured":"Surapaneni SK, Patel N, Sun L, Kommineni N, Kalvala AK, Gebeyehu A, et al. Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45\u03b1, integrin-\u03b15, -\u03b25, -\u03b21, and autophagy. Drug Deliv Transl Res. 2022;12(11):2762\u201377.","journal-title":"Drug Deliv Transl Res"},{"issue":"18","key":"3201_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810103","volume":"22","author":"MA Alsherbiny","year":"2021","unstructured":"Alsherbiny MA, Bhuyan DJ, Low MN, Chang D, Li CG. Synergistic interactions of cannabidiol with chemotherapeutic drugs in MCF7 cells: mode of interaction and proteomics analysis of mechanisms. Int J Mol Sci. 2021;22(18): 10103.","journal-title":"Int J Mol Sci"},{"key":"3201_CR23","doi-asserted-by":"publisher","unstructured":"Gebeyehu A, Kommineni N, Meckes DG Jr, Singh MS. Role of exosomes for delivery of chemotherapeutic drugs. Crit Rev Ther Drug Carrier Syst. 2021;38(5). https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2021036301.","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021036301"},{"issue":"4","key":"3201_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11095-022-03350-7","volume":"40","author":"P Arthur","year":"2023","unstructured":"Arthur P, Kandoi S, Sun L, Kalvala A, Kutlehria S, Bhattacharya S, et al. Biophysical, molecular and proteomic profiling of human retinal organoid-derived exosomes. Pharm Res. 2023;40(4):801\u201316.","journal-title":"Pharm Res"},{"issue":"9","key":"3201_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1023\/A:1025774630993","volume":"20","author":"A Haynes","year":"2003","unstructured":"Haynes A, Shaik MS, Chatterjee A, Singh M. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res. 2003;20(9):1485\u201395.","journal-title":"Pharm Res"},{"issue":"1","key":"3201_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010083","volume":"16","author":"A Nathani","year":"2024","unstructured":"Nathani A, Sun L, Khan I, Aare M, Bagde A, Li Y, et al. Combined role of Interleukin-15 stimulated natural killer cell-derived extracellular vesicles and carboplatin in osimertinib-resistant H1975 lung cancer cells with EGFR mutations. Pharmaceutics. 2024;16(1): 83.","journal-title":"Pharmaceutics"},{"issue":"426","key":"3201_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2025.127161","volume":"15","author":"M Vats","year":"2025","unstructured":"Vats M, Rathod D, Patel H, Richards T, Patel K. Self-emulsifying nano-PND oral delivery systems of PND1186: In silico modeling for bioavailability estimation. J Mol Liq. 2025;15(426): 127161.","journal-title":"J Mol Liq"},{"issue":"4","key":"3201_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jat.4409","volume":"43","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sprando RL. Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. J Appl Toxicol. 2023;43(4):589\u201398.","journal-title":"J Appl Toxicol"},{"issue":"6_Supplement","key":"3201_CR29","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1158\/1538-7445.AM2024-4566","volume":"84","author":"M Aare","year":"2024","unstructured":"Aare M, Khan I, Nathani A, Boirie B, Bagde A, Singh M. Abstract 4566: synergistic anticancer activity of cannabinoids and beta caryophyllene in xenograft mouse model of triple negative breast cancer. Cancer Res. 2024;84(6_Supplement):4566\u20134566.","journal-title":"Cancer Res"},{"issue":"11","key":"3201_CR30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2217\/nnm.16.37","volume":"11","author":"K Patel","year":"2016","unstructured":"Patel K, Doddapaneni R, Chowdhury N, Boakye CH, Behl G, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomed. 2016;11(11):1377\u201392.","journal-title":"Nanomed"},{"issue":"6","key":"3201_CR31","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.2310\/7290.2008.00028","volume":"7","author":"S Biffi","year":"2008","unstructured":"Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E, et al. In vivo biodistribution and lifetime analysis of Cy5.5-conjugated Rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging. 2008;7(6):7290-2008.00028.","journal-title":"Mol Imaging"},{"issue":"1","key":"3201_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-010-1177-4","volume":"129","author":"SD McAllister","year":"2011","unstructured":"McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129(1):37\u201347.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3201_CR33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1124\/jpet.106.105247","volume":"318","author":"A Ligresti","year":"2006","unstructured":"Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):1375\u201387.","journal-title":"J Pharmacol Exp Ther"},{"key":"3201_CR34","doi-asserted-by":"publisher","unstructured":"Badawy AA, Othman RQA, El-Magd MA. Effect of combined therapy with camel milk-derived exosomes, tamoxifen, and hesperidin on breast cancer. Mol Cell Toxicol [Internet]. 2021 Aug 18 [cited 2024 Jan 18]; Available from: https:\/\/doi.org\/10.1007\/s13273-021-00163-4","DOI":"10.1007\/s13273-021-00163-4"},{"issue":"1","key":"3201_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/kvmj.2022.233090","volume":"20","author":"M Ali","year":"2022","unstructured":"Ali M, Elsayed GR, Salama MF, El-Magd MA. Camel milk exosomes had a selective anticancer effect on PANC1 cells and a proliferative effect on H6c7 cells. Kafrelsheikh Vet Med J. 2022;20(1):1\u20135.","journal-title":"Kafrelsheikh Vet Med J"},{"key":"3201_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.procbio.2024.04.007","volume":"142","author":"A Nadaf","year":"2024","unstructured":"Nadaf A, Hasan N, Fauziya, Ahmad S, Gupta A, Jain D, et al. Leucocyte membrane camouflaged poly-lactic-co-glycolic acid (PLGA) nanoparticles containing cannabidiol and paclitaxel against breast cancer therapy. Process Biochem. 2024;142:88\u2013103.","journal-title":"Process Biochem"},{"issue":"8","key":"3201_CR37","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/pharmaceutics14081533","volume":"14","author":"J Fu","year":"2022","unstructured":"Fu J, Zhang K, Lu L, Li M, Han M, Guo Y, et al. Improved therapeutic efficacy of CBD with good tolerance in the treatment of breast cancer through nanoencapsulation and in combination with 20(S)-protopanaxadiol (PPD). Pharmaceutics. 2022;14(8):1533.","journal-title":"Pharmaceutics"},{"issue":"25","key":"3201_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118916","volume":"574","author":"AI Fraguas-S\u00e1nchez","year":"2020","unstructured":"Fraguas-S\u00e1nchez AI, Fern\u00e1ndez-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Su\u00e1rez AI. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. Int J Pharm. 2020;574(25): 118916.","journal-title":"Int J Pharm"},{"issue":"6","key":"3201_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1476-5381.2012.02050.x","volume":"167","author":"M Solinas","year":"2012","unstructured":"Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167(6):1218\u201331.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3201_CR40","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cimb46040227","volume":"46","author":"D B\u0119ben","year":"2024","unstructured":"B\u0119ben D, Siwiela O, Szyjka A, Graczyk M, Rzepka D, Barg E, et al. Phytocannabinoids CBD, CBG, and their derivatives CBD-HQ and CBG-A induced in vitro cytotoxicity in 2D and 3D colon cancer cell models. Curr Issues Mol Biol. 2024;46(4):3626\u201339.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"3201_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers17010016","volume":"17","author":"L Liu","year":"2025","unstructured":"Liu L, Graff SL, Wang Y. New emerging therapies targeting PI3K\/AKT\/mTOR\/PTEN pathway in hormonal receptor-positive and HER2-negative breast cancer\u2014current state and molecular pathology perspective. Cancers. 2025;17(1):16.","journal-title":"Cancers"},{"issue":"12","key":"3201_CR42","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/antiox12122052","volume":"12","author":"A Rybarczyk","year":"2023","unstructured":"Rybarczyk A, Majchrzak-Celi\u0144ska A, Krajka-Ku\u017aniak V. Targeting Nrf2 signaling pathway in cancer prevention and treatment: the role of Cannabis compounds. Antioxidants. 2023;12(12):2052.","journal-title":"Antioxidants"},{"issue":"1","key":"3201_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"6","key":"3201_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13402-018-0398-0","volume":"41","author":"P Sharma","year":"2018","unstructured":"Sharma P, Kumar S. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD). Cell Oncol. 2018;41(6):637\u201350.","journal-title":"Cell Oncol"},{"issue":"1","key":"3201_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1593\/neo.131694","volume":"16","author":"P De","year":"2014","unstructured":"De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia. 2014;16(1):43-W19.","journal-title":"Neoplasia"},{"issue":"11","key":"3201_CR46","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.17219\/acem\/127681","volume":"29","author":"G Li","year":"2020","unstructured":"Li G, Xu D, Sun J, Zhao S, Zheng D. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K\/AKT signaling pathway. Adv Clin Exp Med. 2020;29(11):1337\u201345.","journal-title":"Adv Clin Exp Med"},{"issue":"11","key":"3201_CR47","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798\u2013809.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3201_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"issue":"1","key":"3201_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang R, He S, Long J, Wang Y, Jiang X, Chen M, et al. Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1\/PD-L1 and regulatory pathways. Exp Hematol Oncol. 2024;13(1):46.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"3201_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"157","key":"3201_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bcp.2018.06.025","volume":"1","author":"S Blasco-Benito","year":"2018","unstructured":"Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, Garc\u00eda-Taboada E, et al. Appraising the \u201centourage effect\u201d: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018;1(157):285\u201393.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3201_CR52","doi-asserted-by":"publisher","first-page":"106357","DOI":"10.1016\/j.phrs.2022.106357","volume":"182","author":"J Yang","year":"2022","unstructured":"Yang J, Wang L, Guan X, Qin JJ. Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action. Pharmacol Res. 2022;182(1):106357.","journal-title":"Pharmacol Res"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03201-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:04:21Z","timestamp":1758729861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03201-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3201"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03201-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Animal Care and Use Committee at Florida A&M University, Tallahassee, FL, USA, (protocol code 023\u201302 and Jan 20, 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"ChatGPT 4.0 was used to improve the language in the manuscript. The authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"227"}}